prikaz prve stranice dokumenta Gut Microbiome Composition in Patients with Chronic Urticaria: A Review of Current Evidence and Data
  Download
PDF 4.11 MB
Scientific paper - Review paper
Gut Microbiome Composition in Patients with Chronic Urticaria: A Review of Current Evidence and Data
Life, 13 (2023), 1; 152. https://doi.org/10.3390/life13010152
Krišto, Mirela; Lugović-Mihić, Liborija; Muñoz, Melba; Rupnik, Maja; Mahnic, Aleksander; Ozretić, Petar; Jaganjac, Morana; Ćesić, Diana; Kuna, Matea

Cite this document

Krišto, M., Lugović Mihić, L., Muñoz, M., Rupnik, M., Mahnic, A., Ozretić, P. ... Kuna, M. (2023). Gut Microbiome Composition in Patients with Chronic Urticaria: A Review of Current Evidence and Data. Life, 13. (1). doi: 10.3390/life13010152

Krišto, Mirela, et al. "Gut Microbiome Composition in Patients with Chronic Urticaria: A Review of Current Evidence and Data." Life, vol. 13, no. 1, 2023. https://doi.org/10.3390/life13010152

Krišto, Mirela, Liborija Lugović Mihić, Melba Muñoz, Maja Rupnik, Aleksander Mahnic, Petar Ozretić, Morana Jaganjac, Diana Ćesić and Matea Kuna. "Gut Microbiome Composition in Patients with Chronic Urticaria: A Review of Current Evidence and Data." Life 13, no. 1 (2023). https://doi.org/10.3390/life13010152

Krišto, M., et al. (2023) 'Gut Microbiome Composition in Patients with Chronic Urticaria: A Review of Current Evidence and Data', Life, 13(1). doi: 10.3390/life13010152

Krišto M, Lugović Mihić L, Muñoz M, Rupnik M, Mahnic A, Ozretić P, and sur.. Gut Microbiome Composition in Patients with Chronic Urticaria: A Review of Current Evidence and Data. Life [Internet]. 2023 January 04 [cited 2024 May 09];13(1). doi: 10.3390/life13010152

M. Krišto, et al., "Gut Microbiome Composition in Patients with Chronic Urticaria: A Review of Current Evidence and Data", Life, vol. 13, no. 1, January 2023. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:127:859176. [Accessed: 09 May 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)Gut Microbiome Composition in Patients with Chronic Urticaria: A Review of Current Evidence and Data
AuthorMirela Krišto
AuthorLiborija Lugović-Mihić
MBZ: 215056
AuthorMelba Muñoz
AuthorMaja Rupnik
AuthorAleksander Mahnic
AuthorPetar Ozretić
AuthorMorana Jaganjac
AuthorDiana Ćesić
AuthorMatea Kuna
Author's institutionRuđer Bošković Institute
Author's institution(Sestre milosrdnice University Hospital Center)
Author's institutionUniversity of Zagreb
School of Dental Medicine
(Chair of Dermatovenerology)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Abstract (english)
Recent studies have linked gut microorganism composition and chronic urticaria (CU); however, the underlying mechanisms responsible for this connection are unknown. Since the human immune system is in homeostasis with microbiota, and the composition of the microbiome regulates the development and function of the immune system, it is likely that an alteration of microbiota components (a dysbiosis) could influence the course of chronic spontaneous urticaria (CSU), including disease severity, patient quality of life and treatment outcome. To date, several studies have identified changes in the gut microbiota composition of patients with CSU, though only a few have exhibited metabolic abnormalities associated with gut dysbiosis. The studies on CSU patients predominantly showed that the relative abundance of beneficial bacteria was decreased (Firmicutes and Bacteroides), while that of opportunistic bacteria was increased (Enterobacteria and Proteobacteria). In addition, serum metabolome analysis revealed that gut microbiota-associated alterations in unsaturated fatty acids and the butanoate metabolism pathway may play a role in CSU. These findings are potentially associated with inflammation mediated by the imbalance of Th1/Th2/Th17 cytokines, which might contribute to CSU pathogenesis. Further research in this field could improve clinical, diagnostic, and therapeutic approaches to patients with CSU. By applying new knowledge on gut microbial communities and metabolomics, future CSU therapies could modify the microbiota composition using agents such as probiotics or other similar agents, which, in combination with current standard therapies, could hopefully lead to a reduction in symptoms and an improved quality of life for CSU patients.
Keywords (english)
Languageenglish
Publication typeScientific paper - Review paper
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titleLife
Numberingvol. 13, no. 1, 152
e-ISSN2075-1729
DOIhttps://doi.org/10.3390/life13010152
URN:NBNurn:nbn:hr:127:859176
Publication2023-01-04
Document URLhttps://www.mdpi.com/2075-1729/13/1/152
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2023-03-03 08:59:12